DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR.
Conclusion: Kinetic parameters measured 2.5 weeks post-SABR in both single fraction and three fraction groups were indicative of response but only the single fraction protocol led to enhancement in the surrounding tissue. Our results also suggest that DCE-MRI one-week post-SABR may be too early for response assessment, at least for single fraction SABR, whereas 2.5 weeks appears sufficiently long to minimize confounding acute effects. PMID: 32021911 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 7, 2020 Category: Cancer & Oncology Authors: Mouawad M, Biernaski H, Brackstone M, Lock M, Yaremko B, Shmuilovich O, Kornecki A, Ben Nachum I, Muscedere G, Lynn K, Prato FS, Thompson RT, Gaede S, Gelman N Tags: Clin Transl Radiat Oncol Source Type: research

Efficient dose-finding for drug combination studies involving a shift in study populations.
We describe the adaptation of a model-based design for identifying the maximum tolerated dose combination that efficiently moves from the initial phase in an advanced disease population to the second phase in the target population. Operating characteristics demonstrate the ability of the method to accurately predict true maximum tolerated dose combinations in a high percentage of trials with reasonable sample sizes, while treating participants at and around desirable combinations. The proposed design is a practical, early-phase, adaptive method for use with drug combination dose finding in the presence of shifting patient ...
Source: Clinical Breast Cancer - January 17, 2020 Category: Cancer & Oncology Authors: Wages NA, Millard TA, Dillon PM, Brenin CM, Petroni GR Tags: Contemp Clin Trials Commun Source Type: research

NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy.
Abstract Sentinel lymph node biopsy alone, without complete axillary lymph node dissection, is the standard treatment of the axilla nodal chain in early-stage breast cancer patients presenting a negative sentinel lymph node. The updated results of the IBCSG 23-01 randomized trial recently provided evidence that this approach could be extended to early-stage breast cancer patients presenting only micrometastasis in the sentinel lymph node. On the other hand, patients with large operable or locally advanced breast cancer and clinically positive lymph nodes currently receive neoadjuvant chemotherapy and sentinel lymp...
Source: Clinical Breast Cancer - December 26, 2019 Category: Cancer & Oncology Authors: Tinterri C, Canavese G, Bruzzi P, Dozin B Tags: Contemp Clin Trials Commun Source Type: research

Contemporary Issues in Breast Cancer Radiotherapy.
This article presents recent data informing these contemporary developments in the radiotherapeutic management of breast cancer. PMID: 31739937 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - November 21, 2019 Category: Cancer & Oncology Authors: Braunstein LZ, Bellon JR Tags: Hematol Oncol Clin North Am Source Type: research

Diagnosis Disclosure: Patient Preferences and the Role of the Breast Nurse Navigator.
Abstract BACKGROUND: Receiving a breast cancer diagnosis can be traumatic and anxiety-producing. The way the diagnosis is disclosed to patients can affect their experience. OBJECTIVES: The aim of this article is to determine patient preferences for being informed of a breast cancer diagnosis and the breast nurse navigator (BNN) role during the diagnostic experience. METHODS: A survey was mailed to 517 patients with breast cancer. Summary statistics were performed on 199 completed surveys. FINDINGS: Patients preferred to hear their diagnosis in person. BNNs were more likely to provide the right amoun...
Source: Clinical Breast Cancer - November 16, 2019 Category: Cancer & Oncology Authors: Cantril C, Moore E, Yan X Tags: Clin J Oncol Nurs Source Type: research

Active and Passive Coping Strategies: Comparing Psychological Distress, Cortisol, and Proinflammatory Cytokine Levels in Breast Cancer Survivors.
egi A Abstract BACKGROUND: Breast cancer survivors can experience psychological distress, such as anxiety and depression, long after treatment has ended, and the development of such negative affective states has been related to the coping strategy used. OBJECTIVES: This pilot study aims to determine whether different coping strategies are associated with differences in psychological distress, cortisol, and tumor necrosis factor alpha (TNF-a) levels in breast cancer survivors. METHODS: 54 breast cancer survivors completed the Stress Coping Questionnaire and the Hospital Anxiety and Depression Scale and pr...
Source: Clinical Breast Cancer - November 16, 2019 Category: Cancer & Oncology Authors: Perez-Tejada J, Garmendia L, Labaka A, Vegas O, Gómez-Lazaro E, Arregi A Tags: Clin J Oncol Nurs Source Type: research

Patient Repositioning Reveals a Malignant Pleura Effusion Initially Mistaken as a Bone Metastasis on 18FDG PET/CT.
Abstract A 70-year-old woman with breast cancer underwent F-FDG PET/CT for restaging. An FDG-avid focus corresponding to a rib on CT images was identified and interpreted as suggestive of an osseous metastasis. A PET/CT-guided biopsy was planned with the patient in prone position. Prone images demonstrated the FDG focus "moved" to the anterior chest and corresponding to pleural fluid. The diagnosis was altered from osseous metastases to pleural malignancy, and the bone biopsy was not performed. This case not only emphasizes the sensitivity of PET in the detection of malignancy, but also highlights the di...
Source: Clinical Breast Cancer - November 8, 2019 Category: Cancer & Oncology Authors: Kirchner J, Riedl CC, Ulaner GA Tags: Clin Nucl Med Source Type: research

Study protocol: Randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention.
We describe the study design of a randomized controlled trial examining the effect of two web-based decision support tools on chemoprevention decision antecedents and quality, referral for specialized counseling, and chemoprevention uptake among women at an increased risk for breast cancer. The trial is being conducted at a large, urban medical center. A total of 300 patients and 50 healthcare providers will be recruited and randomized to standard educational materials alone or in combination with the decision support tools. Patient reported outcomes will be assessed at baseline, one and six months after randomization, and...
Source: Clinical Breast Cancer - September 10, 2019 Category: Cancer & Oncology Authors: Crew KD, Silverman TB, Vanegas A, Trivedi MS, Dimond J, Mata J, Sin M, Jones T, Terry MB, Tsai WY, Kukafka R Tags: Contemp Clin Trials Commun Source Type: research

Pegfilgrastim-induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report.
Abstract Dose-dense (DD) chemotherapy is a treatment option for patients with high-risk premenopausal breast cancer. Pegfilgrastim may be administered as prophylaxis against the development of febrile neutropenia and enables the continuation of the DD schedule; however, it is associated with adverse effects, including bone and muscle pain and fatigue. We herein describe our experience with pegfilgrastim administration alongside DD chemotherapy in a patient with breast cancer. A 29-year-old female patient was diagnosed with locally advanced breast cancer during lactation. The patient was diagnosed with cT2N1M0, sta...
Source: Clinical Breast Cancer - September 3, 2019 Category: Cancer & Oncology Authors: Takuwa H, Tsuji W, Goto T, Otsuji T, Yotsumoto F Tags: Mol Clin Oncol Source Type: research

Difficult Diagnosis of Peritoneal Serous Papillary Carcinoma in a 63-year-old Woman: A Case Report.
CONCLUSIONS: The diagnosis and treatment of peritoneal serous papillary carcinoma may be delayed or may not be performed unless Class III findings are detected through uterine mucosal cytology before surgery. Surgeons should not hesitate to perform laparotomy when necessary to identify and appropriately treat patients, even if abnormalities are not detected in the preoperative examination. PMID: 31448396 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 27, 2019 Category: Cancer & Oncology Authors: Tsuda B, Kajiwara H, Sakota N, Amatsu S, Tanaka A, Ikeda M Tags: Tokai J Exp Clin Med Source Type: research

Leveraging system sciences methods in clinical trial evaluation: An example concerning African American women diagnosed with breast cancer via the Patient Navigation in Medically Underserved Areas study.
Discussion: Our study results will provide promising venues for leveraging systems science methodologies in clinical trial evaluation. PMID: 31406947 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 14, 2019 Category: Cancer & Oncology Authors: Molina Y, Khanna A, Watson KS, Villines D, Bergeron N, Strayhorn S, Strahan D, Skwara A, Cronin M, Mohan P, Walton S, Wang T, Schneider JA, Calhoun EA Tags: Contemp Clin Trials Commun Source Type: research

Prognostic factors and survival according to tumor subtype in newly diagnosed breast cancer with liver metastases: A competing risk analysis.
Abstract Population-based study for predicting the prognosis for breast cancer liver metastasis (BCLM) is lacking at present. Therefore, the present study aimed to evaluate newly diagnosed BCLM patients of different tumor subtypes and assess potential prognostic factors for predicting the survival for BCLM patients. Specifically, data were collected from the Surveillance, Epidemiology and End Results program from 2010 to 2014, and were assessed, including the data of patients with BCLM. Differences in the overall survival (OS) among patients was compared via Kaplan-Meier analysis. Other prognostic factors of OS we...
Source: Clinical Breast Cancer - August 11, 2019 Category: Cancer & Oncology Authors: Chen QF, Huang T, Shen L, Wu P, Huang ZL, Li W Tags: Mol Clin Oncol Source Type: research

Imaging features that distinguish pure ductal carcinoma in situ (DCIS) from DCIS with microinvasion.
In conclusion, the presence of calcifications and vascularity on sonography or a lager distribution of calcifications on mammography may suggest DCISM. PMID: 31396390 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 11, 2019 Category: Cancer & Oncology Authors: Wang H, Lin J, Lai J, Tan C, Yang Y, Gu R, Jiang X, Liu F, Hu Y, Su F Tags: Mol Clin Oncol Source Type: research

Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Abstract Lanabecestat is a human β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in development to slow disease progression in patients with early Alzheimer's disease. The study evaluated the breast cancer resistance protein (BCRP) inhibition potential of lanabecestat on the pharmacokinetics (PK) of rosuvastatin, a probe for BCRP activity, in healthy white subjects who were not carriers of SLCO1B1 (c.521T>C), not homozygotes for ABCG2 (c.421C>A or c.34G>A), and not heterozygotes of ABCG2 (c.421C>A and c.34G>A). The safety of lanabecestat + rosuvastatin, the effects of rosuvastatin ...
Source: Clinical Breast Cancer - August 5, 2019 Category: Cancer & Oncology Authors: Willis BA, Andersen SW, Ayan-Oshodi M, James DE, Liffick E, Hillgren K, Guo Y, Monk SA Tags: J Clin Pharmacol Source Type: research

Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer types.
CONCLUSIONS: These findings suggest characteristic DNA methylation changes in EBF3 and TBC1D16 are relatively common tumour-associated epigenetic events in multiple tumour types, which is consistent with a potential role as more general drivers of tumour progression. PMID: 31383000 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 5, 2019 Category: Cancer & Oncology Authors: Rodger EJ, Chatterjee A, Stockwell PA, Eccles MR Tags: Clin Epigenetics Source Type: research

Invasive stratified mucin-producing carcinoma (i-SMILE) of the uterine cervix: report of a case series and review of the literature indicating poor prognostic subtype of cervical adenocarcinoma.
CONCLUSION: i-SMILE represent a distinct subtype of invasive endocervical AC, associated high-risk HPV infection and strong p16-overexpression. Clinically, i-SMILE may represent an aggressive tumor with early recurrent disease and substantial risk of distant metastatic disease, especially to the lungs. PMID: 31385027 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 5, 2019 Category: Cancer & Oncology Authors: Horn LC, Handzel R, Borte G, Siebolts U, Haak A, Brambs CE Tags: J Cancer Res Clin Oncol Source Type: research

Evolution of older patients diagnosed with early breast cancer in Spain between 1998 and 2001 included in El Alamo III project.
AM, the Spanish Breast Cancer Group Abstract INTRODUCTION: An increase in the number of cancer cases is expected in the near future. Breast cancer (BC) mortality rates increase with age even when adjusted for other variables. Here we analyzed BC disease-free survival (BCDFS) and BC specific survival (BCSS) in the El Alamo III BC registry of GEICAM Spanish Breast Cancer Group. MATERIALS AND METHODS: El Alamo III is a retrospective registry of BC patients diagnosed between 1998 and 2001. Patients with stage I-III invasive BC of age groups 55-64 years (y), 70-74 years and ≥ 75 years we...
Source: Clinical Breast Cancer - August 5, 2019 Category: Cancer & Oncology Authors: Torregrosa MD, Escudero MJ, Paredero I, Carrasco E, Bermejo B, Gavila J, García-Saenz J, Santaballa A, Martínez P, Llombart A, Andrés R, Batista N, Fernández A, Antón A, Seguí M, Gonzalez S, Ruiz A, GEICAM, the Spanish Breast Cancer Group Tags: Clin Transl Oncol Source Type: research

A systematic review of the international prevalence of BRCA mutation in breast cancer.
Abstract A systematic review was conducted, summarizing international BRCA 1 or 2 (BRCA1/2) mutation prevalence in breast cancer. Databases (eg, Medline and Embase; N=7) and conferences were searched (January 2012 to December 2017). From 17,872 records, 70 studies were included. In 58 large (N>100) studies, BRCA1/2 mutation prevalence varied widely from 1.8% (Spain) in sporadic breast cancer to 36.9% (United States) in estrogen receptor/progesterone receptor low+ (1-9% on immunohistochemistry/human epidermal growth factor receptor 2-negative [HER2-]) breast cancer. In 2 large studies unselected for family histo...
Source: Clinical Breast Cancer - August 4, 2019 Category: Cancer & Oncology Authors: Armstrong N, Ryder S, Forbes C, Ross J, Quek RG Tags: Clin Epidemiol Source Type: research

Quantification of PpIX-fluorescence of cerebral metastases: a pilot study.
F, Kamp MA Abstract 5-ALA fluorescence-guided surgery (FGS) is a major advance in neuro-oncological surgery. So far, Protoporphyrin IX (PpIX)-fluorescence has been observed in about half of cerebral metastases resected with routinely equipped microscopes during 5-ALA FGS. The aim of the present pilot study was to quantify PpIX-induced fluorescence of cerebral metastases with a spectrometer. We hypothesize that non-fluorescing metastases under the operating microscope may have spectrometrically measurable levels of fluorescence. A second aim was to analyze correlations between quantified 5-ALA fluorescence and hist...
Source: Clinical Breast Cancer - August 2, 2019 Category: Cancer & Oncology Authors: Knipps J, Fischer I, Neumann LM, Rapp M, Dibué-Adjei M, Freiin von Saß C, Placke JM, Mijderwijk HJ, Steiger HJ, Sabel M, Cornelius JF, Kamp MA Tags: Clin Exp Metastasis Source Type: research

AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs).
CONCLUSIONS: In the present study we have provided novel insights regarding the molecular mechanisms by which 3MC may trigger a physical and functional interaction between AHR and GPER, leading to the stimulation of both SkBr3 breast cancer cells and CAFs. Altogether, our results indicate that 3MC may engage both GPER and AHR transduction pathways toward breast cancer progression. PMID: 31370872 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 1, 2019 Category: Cancer & Oncology Authors: Cirillo F, Lappano R, Bruno L, Rizzuti B, Grande F, Guzzi R, Briguori S, Miglietta AM, Nakajima M, Di Martino MT, Maggiolini M Tags: J Exp Clin Cancer Res Source Type: research

Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients.
CONCLUSIONS: These results raise the question whether axillary node status is redundant in cases with exceptionally good features, i.e., small tumors with low Ki67, or in those candidate to adjuvant systemic treatment/radiotherapy anyway including TNBC, and support the incorporation of primary BC tumor characteristics as stratification factors in ongoing trials aiming at de-escalating axillary surgical procedures. PMID: 31372896 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 1, 2019 Category: Cancer & Oncology Authors: De Santis MC, La Rocca E, Meneghini E, Bregni G, Di Lorenzo G, Galli G, Di Nicola M, Folli S, Gennaro M, Pruneri G, Paolini B, Daidone MG, De Braud F, Apolone G, Sant M, Di Cosimo S Tags: Clin Transl Oncol Source Type: research

Adipose Tissue Distribution and Cardiovascular Disease Risk Among Breast Cancer Survivors.
CONCLUSION: Visceral and intramuscular adiposity were associated with increased CVD incidence after breast cancer diagnosis, independent of pre-existing CVD risk factors and cancer treatments. The increased CVD incidence among normal-weight patients with greater visceral adiposity would go undetected with BMI alone. Measures of adipose tissue distribution may help identify high-risk patients and tailor CVD prevention strategies. PMID: 31369302 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 1, 2019 Category: Cancer & Oncology Authors: Cespedes Feliciano EM, Chen WY, Bradshaw PT, Prado CM, Alexeeff S, Albers KB, Castillo AL, Caan BJ Tags: J Clin Oncol Source Type: research

Learning Health System for Breast Cancer: Pilot Project Experience.
CONCLUSION: It is possible to extract, read, and combine data from the EHR to view the patient journey. The agreement between NLP and the gold standard was high, which supports validity. PMID: 31369338 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - August 1, 2019 Category: Cancer & Oncology Authors: Levine MN, Alexander G, Sathiyapalan A, Agrawal A, Pond G Tags: JCO Clin Cancer Inform Source Type: research

Targeted Therapies: Treatment Options for Patients With Metastatic Breast Cancer.
This article reviews targeted therapy treatment options for patients with metastatic BC, including strategies for administration, side effects, and nursing considerations. PMID: 31322617 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 21, 2019 Category: Cancer & Oncology Authors: Richards R, Keating E, Boucher JE Tags: Clin J Oncol Nurs Source Type: research

Cutaneous and breast metastasis from colorectal adenocarcinoma: A rare case report.
Abstract Synchronous breast and cutaneous metastases from colorectal adenocarcinoma as the initial clinical manifestation, without visceral metastases, are extremely rare. We herein report the case of a 68-year-old female patient who presented with pruritic skin lesions and a breast lump 6 years after abdominoperineal resection of colorectal adenocarcinoma. Such cases can be easily misdiagnosed as cutaneous metastasis from breast cancer. However, the management of colorectal metastases differs from that of primary breast cancer, and mastectomy may be unnecessary. Timely and accurate diagnosis requires a high level...
Source: Clinical Breast Cancer - July 11, 2019 Category: Cancer & Oncology Authors: Liao XY, Liu CY, Liang LB, Du JR, Zhang T Tags: Mol Clin Oncol Source Type: research

Are data from general practices suitable for survival analyses in the field of breast cancer? A retrospective study conducted in the United Kingdom, France and Germany.
This study included women diagnosed with BC between 2004 and 2008 in 416, 322 and 210 general practices in the UK (n=4,085), France (n=1,198) and Germany (n=2,934), respectively. The outcomes of the study were the mean duration of follow-up in years and the proportion of participants followed for at least 5 years. The mean duration of follow-up was 7.5-9.6 years in the UK, 7.4-8.8 years in France and 6.3-8.5 years in Germany. The proportion of patients followed for at least 5 years was 80-91% in the UK, 68-78% in France, and 55-76% in Germany. The data obtained in general practices in the UK appeared to be more suitable fo...
Source: Clinical Breast Cancer - July 11, 2019 Category: Cancer & Oncology Authors: Jacob L, Kalder M, Haas G, Kostev K Tags: Mol Clin Oncol Source Type: research

Molecular characteristics of breast cancer according to clinicopathological factors.
In conclusion, BRCA1 mutation was associated with TNBC and the luminal B HER2 (-) subtype. HER2-positive subtypes were characteristic of the control group. CHEK2 and NOD2 mutation carriers had a more favorable profile of prognostic factors. PMID: 31281656 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 11, 2019 Category: Cancer & Oncology Authors: Huszno J, Kolosza Z Tags: Mol Clin Oncol Source Type: research

Breast Cancer Demographics, Types and Management Pathways: Can Western Algorithms be Optimally used in Eastern Countries?
Abstract Over the past decade, breast cancer has overtaken cervical cancer to become the most common cancer among women in India, as in most Western nations. In addition to the high incidence, the morbidity and mortality associated with this malignancy are disproportionately higher in India. Although some efforts are being made to increase awareness about this disease, a large majority of Indian patients present with advanced disease. Here, important institutional data and treatment outcomes are reviewed and compared with data from the West. Additionally, we highlight recent efforts in setting up collaborative mul...
Source: Clinical Breast Cancer - July 8, 2019 Category: Cancer & Oncology Authors: Chakraborty S, Wadasadawala T, Ahmed R, Coles C, Chatterjee S Tags: Clin Oncol (R Coll Radiol) Source Type: research

A Comparison of Angiogenesis and Glycolytic Imaging in Patients With Clinical Suspected Locally Advanced Breast Cancer.
Abstract F-FDG PET/CT imaging is an important diagnostic tool for accurate staging and assessment of response to neoadjuvant chemotherapy (NACT) in patients with locally advanced breast carcinoma (LABC). However, F-FDG being non-specific marker, it also accumulates in inflammatory conditions, leading to false positive results. Angiogenesis, an essential characteristic for tumor development, intrusion and metastasis can be imaged using Ga-labeled RGD tripeptide. We here depict a series of clinically staged LABC patients who underwent both Ga-DOTA-RGD2 and F-FDG PET/CT imaging for staging and illustrate the similari...
Source: Clinical Breast Cancer - July 7, 2019 Category: Cancer & Oncology Authors: Vatsa R, Ashwathanarayana AG, Singh G, Kavanal AJ, Kumar S, Rana N, Shukla J, Mittal BR Tags: Clin Nucl Med Source Type: research

High expression of DLG3 is associated with decreased survival from breast cancer.
This article is protected by copyright. All rights reserved. PMID: 31271664 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 4, 2019 Category: Cancer & Oncology Authors: Liu J, Li P, Wang R, Li J, Zhang M, Song Z, Liu P Tags: Clin Exp Pharmacol Physiol Source Type: research

Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.
CONCLUSION: Despite conflicting results in the literature, our study clearly shows a better outcome of PIK3CA-expressing TNBC, independent of TNBC subtypes. PIK3CA expression in TNBC is not associated with specific clinical or diagnostic features. Further molecular studies and meta-analysis are warranted to clarify the prognostic and predictive role of PIK3CA protein expression. PMID: 31270600 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 3, 2019 Category: Cancer & Oncology Authors: Elfgen C, Reeve K, Moskovszky L, Güth U, Bjelic-Radisic V, Fleisch M, Tausch C, Varga Z Tags: J Cancer Res Clin Oncol Source Type: research

Role of boost radiotherapy for local control of pure ductal carcinoma in situ after breast-conserving surgery: a multicenter, retrospective study of 622 patients.
CONCLUSIONS: Radiotherapy boost did not improve the risk of IBTR. Boost radiotherapy was more common in patients with high-risk disease. Tumor size and re-excision were significant independent prognostic factors. PMID: 31264148 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Cambra MJ, Moreno F, Sanz X, Anglada L, Mollà M, Reyes V, Arenas M, Pedro A, Ballester R, García V, Casals J, Cusidó M, Jimenez C, Escribà JM, Macià M, Solé JM, Arcusa A, Seguí MA, Gonzalez S, Farrús B, Biete A Tags: Clin Transl Oncol Source Type: research

Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study.
CONCLUSION: Use of mailed materials followed by telephone-delivered counseling increased mammography screening rates in survivors at high risk for breast cancer; however, this approach did not increase the rate of breast MRI. Cost of imaging and physician recommendation were important barriers that should be addressed in future studies. PMID: 31260642 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Oeffinger KC, Ford JS, Moskowitz CS, Chou JF, Henderson TO, Hudson MM, Diller L, McDonald A, Ford J, Mubdi NZ, Rinehart D, Vukadinovich C, Gibson TM, Anderson N, Elkin EB, Garrett K, Rebull M, Leisenring W, Robison LL, Armstrong GT Tags: J Clin Oncol Source Type: research

Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
We describe the ensuing risk for mortality and additional breast cancers. PATIENTS AND METHODS: Female participants in the Childhood Cancer Survivor Study, a cohort of 5-year survivors of cancer diagnosed between 1970 and 1986 before age 21 years, and subsequently diagnosed with breast cancer (n = 274; median age at breast cancer diagnosis, 38 years; range, 20 to 58 years) were matched to a control group (n = 1,095) with de novo breast cancer. Hazard ratios (HRs) and 95% CIs were estimated from cause-specific proportional hazards models. RESULTS: Ninety-two childhood cancer survivors died, 49 as a result of breas...
Source: Clinical Breast Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Moskowitz CS, Chou JF, Neglia JP, Partridge AH, Howell RM, Diller LR, Novetsky Friedman D, Barnea D, Morton LM, Turcotte LM, Arnold MA, Leisenring WM, Armstrong GT, Robison LL, Oeffinger KC, Henderson TO Tags: J Clin Oncol Source Type: research

Predicting the risk of locoregional recurrence after early breast cancer: an external validation of the Dutch INFLUENCE-nomogram with clinical cancer registry data from Germany.
The objective of this study is to validate the prediction tool on non-Dutch patients. MATERIAL AND METHODS: Data for this external validation derive from a large clinical cancer registry in southern Germany, covering a population of 1.1 million. Patients with curative resection of early-stage breast cancer, diagnosed between 2000 and 2012, were included in the analysis (n = 6520). For each of them, an individual LRR-risk was estimated by the INFLUENCE-nomogram. Its predictive ability was tested by comparing estimated and observed LRR-probabilities using the Hosmer-Lemeshow goodness-of-fit test and C...
Source: Clinical Breast Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Voelkel V, Draeger T, Groothuis-Oudshoorn CGM, de Munck L, Hueting T, Gerken M, Klinkhammer-Schalke M, Lavric M, Siesling S Tags: J Cancer Res Clin Oncol Source Type: research

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype.
CONCLUSION: We confirm previous studies showing that the PTPN2 protein is lost in half of the breast cancer cases and gene deletion occurs in 15-18% of the cases. Furthermore, the results suggest that the role of PTPN2 is subtype-related and should be further investigated to assess how this could affect breast cancer prognosis and treatment response. PMID: 31025094 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Veenstra C, Karlsson E, Mirwani SM, Nordenskjöld B, Fornander T, Pérez-Tenorio G, Stål O Tags: J Cancer Res Clin Oncol Source Type: research

Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
Abstract PURPOSE: Ductal carcinoma in situ (DCIS) is widely recognized as the precursor of invasive ductal carcinoma (IDC). We aimed to analyze the clinicopathological characteristics and clinical outcomes of coexisting DCIS component in IDC and its clinical significance according to molecular subtypes. METHODS: Data from 3001 patients with IDC (79.4%) and IDC/DCIS (20.6%) who underwent surgery from January 2009 to June 2016 were retrospectively assessed. The clinical outcomes of IDC with coexistent DCIS in different molecular subtypes were evaluated. RESULTS: IDC/DCIS patients were more likely to be younger (P 
Source: Clinical Breast Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Goh CW, Wu J, Ding S, Lin C, Chen X, Huang O, Chen W, Li Y, Shen K, Zhu L Tags: J Cancer Res Clin Oncol Source Type: research

Vaccine Therapies for Breast Cancer.
Abstract Vaccines can be a cost effective preventive measure for both primary prevention of disease and prevention of disease recurrence. Several vaccines targeting breast cancer oncodrivers are currently being tested in clinical trials. Whereas clinical response rates to breast cancer vaccines have been modest despite the induction of strong antitumor T cell responses, it is through these approaches that valuable insight and knowledge have been gained about tumor immunology. With the emergence of new immunotherapies, there is renewed excitement for effective breast cancer vaccine development. PMID: 3107...
Source: Clinical Breast Cancer - May 15, 2019 Category: Cancer & Oncology Authors: Burke EE, Kodumudi K, Ramamoorthi G, Czerniecki BJ Tags: Surg Oncol Clin N Am Source Type: research

Corrigendum to "Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial" [Contemp. Clin. Trials Commun. 12 (2018) 109-115].
Corrigendum to "Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial" [Contemp. Clin. Trials Commun. 12 (2018) 109-115]. Contemp Clin Trials Commun. 2019 Jun;14:100349 Authors: Chalela P, Munoz E, Inupakutika D, Kaghyan S, Akopian D, Kaklamani V, Lathrop K, Ramirez A Abstract [This corrects the article DOI: 10.1016/j.conctc.2018.10.001.]. PMID: 31049460 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 4, 2019 Category: Cancer & Oncology Authors: Chalela P, Munoz E, Inupakutika D, Kaghyan S, Akopian D, Kaklamani V, Lathrop K, Ramirez A Tags: Contemp Clin Trials Commun Source Type: research

Long-term outcome following sentinel node navigation surgery for cT1 gastric cancer.
Abstract Sentinel node navigation surgery (SNNS) has become a standard procedure for early-stage melanoma and breast cancer. However, very few studies have evaluated the long-term clinical outcomes following SNNS for gastric cancer. The present study analyzed 51 patients with cT1 gastric cancer who underwent SNNS at our hospital. Sentinel nodes (SNs) were identified using the dual tracer method. Patients underwent limited gastrectomy with SN station dissection when the SNs were reported as pathologically negative during surgery. When SNs were pathologically positive, standard gastrectomy with D2 lymphadenectomy wa...
Source: Clinical Breast Cancer - May 1, 2019 Category: Cancer & Oncology Authors: Yaguchi Y, Tsujimoto H, Hiraki S, Ito N, Nomura S, Horiguchi H, Kumano I, Einama T, Okamoto K, Noro T, Kajiwara Y, Shinto E, Aosasa S, Ichikura T, Ueno H Tags: Mol Clin Oncol Source Type: research

Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort.
In conclusion, the data from the present study emphasize the high incidence of BRCA2 mutation in male BC, and its association with FH, bilaterality, high Ki-67 expression, negative PR expression and Luminal B-like subtypes, and with shorter DFS and OS in univariate analysis. PMID: 31031981 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2019 Category: Cancer & Oncology Authors: André S, Pereira T, Silva F, Machado P, Vaz F, Aparício M, Silva GL, Pinto AE Tags: Mol Clin Oncol Source Type: research

Evaluation of organ motion-based robust optimisation for VMAT planning for breast and internal mammary chain radiotherapy.
In this study we describe and validate organ motion-based robust optimisation for generating breast and locoregional lymph node VMAT plans that are robust to inter-fractional changes. Materials and methods: In this retrospective study of five patients with left-sided breast cancer requiring locoregional breast radiotherapy including the IMC, non-robust plans were generated in the nominal scenario (planning-CT) and corresponding robust plans were created by optimising over a range of simulated CTs representing worst-case scenario shape changes to the breast. Both plans were re-calculated on CBCT images (n = 67) acq...
Source: Clinical Breast Cancer - May 1, 2019 Category: Cancer & Oncology Authors: Dunlop A, Colgan R, Kirby A, Ranger A, Blasiak-Wal I Tags: Clin Transl Radiat Oncol Source Type: research

The use of aloe vera in cancer radiation: An updated comprehensive review.
CONCLUSIONS: There is contradictory evidence for the use of aloe vera in the setting of radiation in regards to its efficacy in the prevention and treatment of radiation-induced adverse effects. PMID: 31003648 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 22, 2019 Category: Cancer & Oncology Authors: Farrugia CE, Burke ES, Haley ME, Bedi KT, Gandhi MA Tags: Complement Ther Clin Pract Source Type: research

Use of complementary and alternative medicine among breast cancer patients in Hungary: A descriptive study.
This study aimed to explore the prevalence of the use of complementary and alternative medicine (CAM) before diagnosis and during oncology therapy, and reveal the disclosure of CAM use among Hungarian breast cancer patients. MATERIALS AND METHODS: In a cross-sectional survey a self-administered questionnaire was used covering patients' demographics, oncology-related variables and various aspects of CAM use. Data were collected from 135 patients. Data analysis included descriptive analysis and Chi-square tests. RESULTS: The prevalence of CAM use was 52.6% before diagnosis while it was 84.4% during therapy. The mos...
Source: Clinical Breast Cancer - April 22, 2019 Category: Cancer & Oncology Authors: Sárváry A, Sárváry A Tags: Complement Ther Clin Pract Source Type: research

Overexpression of ECT2 is a strong poor prognostic factor in ER(+) breast cancer.
Abstract Epithelial cell transforming sequence 2 (ECT2) is a guanine nucleotide exchange factor encoded by the ECT2 gene, which is located on the 3q26.31 chromosomal region and is directly associated with the occurrence of cancers. The aim of the present study was to examine the expression and prognostic importance of ECT2 in various breast cancer subtypes using the online tools, Gene Expression Profiling Interactive Analysis, Kaplan-Meier-plotter and bc-GenExMiner. ECT2 mRNA expression was significantly different in oestrogen receptor ER(+) breast cancer; overexpression of ECT2 was associated with poor prognosis ...
Source: Clinical Breast Cancer - April 12, 2019 Category: Cancer & Oncology Authors: Xiu Y, Liu W, Wang T, Liu Y, Ha M Tags: Mol Clin Oncol Source Type: research

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.
Conclusions: This meta-analysis shows that the addition of platinum to chemotherapy regimens in the neoadjuvant setting increases pCR rate in BRCA - mutated as compared to wild-type TNBC patients. However, this trend did not achieve statistical significance. Trial registration: CRD42018092341. PMID: 30962858 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 11, 2019 Category: Cancer & Oncology Authors: Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T Tags: Hered Cancer Clin Pract Source Type: research

Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature.
Abstract Background: Neurofibromatosis type 1 (NF1) is a cancer predisposing syndrome. Studies suggest that women
Source: Clinical Breast Cancer - April 11, 2019 Category: Cancer & Oncology Authors: Suarez-Kelly LP, Yu L, Kline D, Schneider EB, Agnese DM, Carson WE Tags: Hered Cancer Clin Pract Source Type: research

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
CONCLUSION: Clinically-tested patients with breast and ovarian cancer in two large, diverse states had 8% to 15% prevalence of actionable pathogenic variants. Substantial testing gaps and disparities among patients with ovarian cancer are targets for improvement. PMID: 30964716 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 9, 2019 Category: Cancer & Oncology Authors: Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, Miller D, Penberthy LS, Katz SJ Tags: J Clin Oncol Source Type: research

GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.
CONCLUSION: Our results reveal that GTSE1 played a key role in the progression of breast cancer, indicating that GTSE1 could serve as a novel biomarker to aid in the assessment of the prognosis of breast cancer. PMID: 30961661 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 8, 2019 Category: Cancer & Oncology Authors: Lin F, Xie YJ, Zhang XK, Huang TJ, Xu HF, Mei Y, Liang H, Hu H, Lin ST, Luo FF, Lang YH, Peng LX, Qian CN, Huang BJ Tags: J Exp Clin Cancer Res Source Type: research

Impact of the 2018 ASCO/CAP HER2 Guideline Focused Update.
CONCLUSIONS: The 2018 guidelines decrease the rate of HER2 equivocal and positive breast cancer and reduce repeat HER2 testing on excision specimens. Approximately 0.4% of patients will become newly ineligible for anti-HER2 therapy. PMID: 30958889 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 8, 2019 Category: Cancer & Oncology Authors: Gordian-Arroyo AM, Zynger DL, Tozbikian GH Tags: Am J Clin Pathol Source Type: research